Roche To Present Breast Cancer Data At San Antonio Symposium
Roche Holding AG (ROG.VX) Wednesday said it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the San Antonio Breast Cancer Symposium starting Dec. 6.
MAIN FACTS:
- This includes data from the first randomised Phase III study of pertuzumab in combination with Herceptin and docetaxel chemotherapy (CLEOPATRA).
- The mechanisms of action of pertuzumab and Herceptin are believed to complement each other as both bind to the HER2 receptor but on different regions.
- "We are making additional substantial progress against HER2-positive breast cancer, a disease for which we have already dramatically changed the standard of care and improved patient outcomes," said Hal Barron, chief medical officer and head, Global Product Development. "Data at this conference reaffirm our commitment to discovering new treatments for HER2-positive breast cancer."
- Data from the VIRGO metastatic breast cancer registry will also be presented.
- These emphasise the importance of accurate HER2 diagnostic testing in ensuring that the HER2 status of breast cancer is accurately identified, and that people subsequently receive appropriate treatment for their disease.
-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com
